The Neurogenic Bladder<\/a> Symptom Score (NBSS) is an internationally recognized, disease-specific patient-reported outcome measure<\/a> (PROM) engineered to assess the subjective severity, clinical consequences, and psychosocial burden of neurogenic lower urinary tract dysfunction (NLUTD). Developed initially to address the clinical shortcomings of generic urological questionnaires\u2014which regularly presuppose volitional voiding and ignore neuro-urological management techniques such as clean intermittent catheterization<\/a>\u2014the NBSS provides a nuanced, multidimensional appraisal of lower urinary tract symptoms across clinical cohorts, including individuals with spinal cord injury<\/a>, multiple sclerosis<\/a>, and spina bifida<\/a>.<\/p>\n The Brazilian Portuguese cross-cultural adaptation and psychometric validation of the NBSS operationalizes this specialized instrument for Portuguese-speaking clinical and research environments. Comprising 24 items, the scale evaluates three core symptom domains: Incontinence (8 items), Storage and Voiding symptoms (7 items), and clinical Consequences (7 items), alongside two independent items that capture the primary bladder management strategy (Question 1) and global urinary-specific quality of life (Question 24). Total scores on the clinical symptom subscales range from 0 to 74, where elevated values represent heightened symptom severity, frequent adverse sequelae, and pronounced functional impairment.<\/p>\n Psychometric evaluation demonstrates strong internal consistency, evidenced by an overall Cronbach’s alpha of 0.81, and excellent temporal stability over a 7- to 14-day retest interval with an intraclass correlation coefficient<\/a> (ICC) of 0.86. Construct validity is supported by significant convergent correlation with the Short Form of the Qualiveen questionnaire (Qualiveen-SF; r<\/em> = 0.66, p<\/em> < 0.001) and robust known-groups discriminant validity through analysis of variance (ANOVA) across subjective problem categories. The instrument exhibits semantic, idiomatic, and conceptual equivalence with the original English version, cementing its status as an essential clinical trial endpoint and longitudinal monitoring tool in neuro-rehabilitation<\/span>.<\/p>\n neurogenic bladder, lower urinary tract symptoms, patient-reported outcome measures, psychometrics, spinal cord injury, urinary incontinence, cross-cultural adaptation, quality of life, neuro-urology, construct validity, test-retest reliability, Qualiveen<\/p>\n The original conceptualization and development of the Neurogenic Bladder Symptom Score was spearheaded by Dr. Blayne Welk<\/strong> and colleagues at the Department of Surgery (Division of Urology) and the Department of Epidemiology and Biostatistics at Western University (London, Ontario, Canada). The Brazilian Portuguese adaptation and psychometric validation was conducted by an interdisciplinary consortium of urologists, physiatrists, and neuro-urology researchers from the University of S\u00e3o Paulo:<\/p>\n Neurogenic lower urinary tract dysfunction (NLUTD) constitutes one of the most debilitating, medically complex, and psychosocially disruptive secondary conditions secondary to acquired or congenital nervous system lesions. Conditions such as traumatic spinal cord injury (SCI), multiple sclerosis (MS), transverse myelitis, and myelomeningocele severely disrupt the neural coordination between the brainstem, spinal autonomic centers, and peripheral detrusor-sphincter mechanisms. Historically, clinical evaluation of this population leaned disproportionately on objective urodynamic parameters (e.g., detrusor leak point pressure, bladder compliance, maximum cystometric capacity) and clinician-observed sequelae.<\/p>\n Although urodynamic metrics remain the gold standard for preserving renal safety and stratifying upper urinary tract deterioration risks, they correlate poorly with day-to-day patient experiences, functional independence, and health-related quality of life (HRQoL). Conversely, traditional patient-reported questionnaires utilized in general urology\u2014such as the International Prostate Symptom Score<\/a> (IPSS) or the Overactive Bladder<\/a> Questionnaire (OAB-q)\u2014were calibrated around non-neurogenic, volitionally voiding populations. These instruments focus primarily on symptoms like hesitancy, strain, post-void dribbling, and nocturia, rendering them structurally inappropriate for patients relying on clean intermittent catheterization, indwelling suprapubic tubes, or reflexive condom collections. Furthermore, generic instruments omit life-threatening complications unique to neurogenic pathologies, such as autonomic dysreflexia<\/a>, deep pelvic spasticity, and insidious, asymptomatic urinary tract infections (UTIs).<\/p>\n The NBSS was formulated to resolve this measurement disparity by establishing a psychometrically sound, standardized instrument specifically designed to quantify the multifaceted manifestations of neurogenic bladder. The purpose of the Brazilian Portuguese adaptation by Cintra and colleagues (2019) was to provide a linguistically, culturally, and psychometrically validated instrument for clinical care and academic research in Brazil. In clinical settings, the NBSS operationalizes symptom severity to guide pharmacological escalation (such as anticholinergics or beta-3 agonists), evaluate surgical interventions (e.g., intradetrusor onabotulinumtoxinA injections, augmentation cystoplasty, or urinary diversion), and detect subclinical decompensation before irreversible upper tract damage ensues. In research paradigms, the adapted NBSS affords a robust, cross-culturally comparable clinical endpoint, facilitating the integration of Latin American patient cohorts into international multi-center neuro-urological trials.<\/p>\n The core construct operationalized by the Neurogenic Bladder Symptom Score is neurogenic bladder symptom burden and functional interference<\/em>. In psychometric and health psychology terms, this construct reflects the patient’s subjective appraisal of lower urinary tract impairment, secondary somatic complications, and the resulting disruption to daily behavioral, emotional, and social functioning. Rather than conceptualizing bladder pathology as a unidimensional physiological deficit, the NBSS models symptom burden as a multidimensional construct encompassing three interrelated clinical domains and an overarching health-related quality of life appraisal.<\/p>\n The Incontinence domain (Items 2 to 9) captures the frequency, volume, and contextual phenomenology of involuntary urine loss. In neurogenic populations, urinary leakage often stems from neurogenic detrusor overactivity<\/a> (NDO), intrinsic sphincter deficiency, or mechanical catheter bypass. The domain explores:<\/p>\n The Storage and Voiding domain (Items 10 to 16) examines the mechanical, sensory, and behavioral barriers encountered during the reservoir and evacuation phases of micturition. Because individuals with neurogenic dysfunction exhibit diverse bladder behaviors\u2014ranging from complete detrusor areflexia to violent detrusor-sphincter dyssynergia (DSD)\u2014this domain addresses:<\/p>\n The Consequences domain (Items 17 to 23) represents the most clinically differentiated aspect of the NBSS, tapping into neuro-urological sequelae not found in generic urological scales:<\/p>\n The construct is bookended by two independent evaluative items. Question 1 identifies the primary bladder management modality (e.g., spontaneous voiding, clean intermittent self-catheterization, catheterization by a caregiver, indwelling urethral catheter, suprapubic cystostomy, or urinary diversion). Question 24 provides a global, summative index of urinary-specific quality of life using a Delighted-to-Terrible rating scale, operationalizing the respondent’s affective adaptation to life with neurogenic lower urinary tract dysfunction.<\/p>\n The development and cross-cultural validation of the Neurogenic Bladder Symptom Score is underpinned by two complementary frameworks: the Wilson and Cleary Model of Health-Related Quality of Life<\/strong> and the World Health Organization’s International Classification of Functioning, Disability and Health (WHO-ICF)<\/strong>.<\/p>\n The Wilson and Cleary conceptual model (1995) delineates health outcomes along a continuum of increasing complexity, progressing from biological and physiological variables to symptom status, functioning, general health perceptions, and overall quality of life:<\/p>\n By explicitly bridging the gap between physiological impairment (urodynamic metrics) and global quality of life, the NBSS captures the intermediate symptom and functional domains that dictate clinical intervention success from the patient’s vantage point.<\/p>\n Under the ICF framework, disability is conceptualized not as a purely medical defect, but as a dynamic interaction between health conditions, body functions\/structures, activity limitations, and participation restrictions:<\/p>\n The NBSS systematically integrates these layers, offering clinicians a psychometric profile of how biological neurological impairment translates into daily activity limitations and personal disruption.<\/p>\n The psychometric validation of the Brazilian Portuguese Neurogenic Bladder Symptom Score executed by Cintra et al. (2019) followed international guidelines for the cross-cultural adaptation of self-report measures established by Beaton and Guillemin. Validation involved verifying content, convergent, and known-groups construct validity within a dedicated neurogenic population.<\/p>\n Content validity was evaluated by an expert multidisciplinary committee consisting of three academic urologists specializing in neuro-urology, a female pelvic medicine and reconstructive surgeon (urogynecologist), a physiatrist, and professional linguists. The committee analyzed forward-translations and back-translations, resolving discrepancies in idiomatic phrasing and confirming that every item mapped accurately to clinical realities experienced by Brazilian patients with spinal injuries and neurological diseases. Pre-testing in a pilot cohort of patients confirmed semantic clarity, item comprehensibility, and high face validity across various educational backgrounds.<\/p>\n Convergent validity was examined by comparing the NBSS total score against the Brazilian Portuguese version of the Qualiveen-SF<\/strong> (Short Form Qualiveen<\/a>), a validated disease-specific quality of life questionnaire for neurogenic urinary disorders. The bivariate correlation analysis revealed a statistically significant, moderate-to-strong positive correlation:<\/p>\n Because higher scores on both the NBSS and Qualiveen-SF signify greater symptom severity and worse quality of life, this strong positive association demonstrates that the NBSS accurately captures the underlying target construct of urinary-related health impairment.<\/p>\n Known-groups validity was tested to determine whether the NBSS could differentiate between clinical subgroups with distinct symptom severities. Participants rated their global bladder trouble on a single-item Likert scale categorized into ordinal tiers (e.g., mild, moderate, severe problem). A one-way analysis of variance (ANOVA) demonstrated a significant linear gradient across groups:<\/p>\n This progressive step-up in scores confirms that the instrument possesses excellent discriminant sensitivity to clinical severity, accurately reflecting the subjective magnitude of urological impairment.<\/p>\n The reliability of the Brazilian Portuguese NBSS was evaluated through rigorous assessments of internal consistency and test-retest reproducibility across stable clinical participants.<\/p>\n Internal consistency was calculated using Cronbach’s alpha<\/a> on the overall questionnaire items. The scale demonstrated robust internal consistency:<\/p>\n This coefficient exceeds the universally accepted psychometric threshold of 0.70 for exploratory research and meets the 0.80 benchmark recommended for clinical assessment tools. This value indicates high interrelatedness among items without excessive redundancy, confirming that the distinct symptom domains contribute harmoniously to a unified measurement of neurogenic bladder burden.<\/p>\n To evaluate stability over time, the NBSS was re-administered to a subsample of clinically stable participants across a standardized interval of 7 to 14 days. During this wash-out period, no medical alterations, medication titrations, or surgical procedures were performed. Reproducibility was quantified using the two-way mixed-effects intraclass correlation coefficient<\/a> (ICC) for absolute agreement:<\/p>\n An ICC value of 0.86 indicates excellent reproducibility and minimal random measurement error, verifying that the Brazilian Portuguese NBSS provides stable baseline data suitable for longitudinal clinical monitoring and pharmaceutical intervention trials.<\/p>\n In their cross-cultural adaptation study, Cintra et al. (2019) retained the structural architecture established during the original instrument development by Welk et al. (2013, 2014) rather than deriving a de novo factor structure via exploratory factor analysis (EFA). The conceptual and psychometric rationale for this decision was rooted in the sample size constraints typical of specialized neuro-trauma cohorts and the imperative to maintain direct structural equivalence with the international parent scale.<\/p>\n During the primary English validation across 197 neurological patients, Welk and colleagues employed item-to-subscale correlations, principal component techniques, and clinical expert panels to construct a three-factor solution:<\/p>\n The Brazilian validation confirmed that the three-factor tripartite structure preserved strong conceptual fidelity in the target population. While formal confirmatory factor analysis<\/a> (CFA) fit indices (e.g., RMSEA, CFI, TLI) were not computed due to the modest sample size (n<\/em> = 68), the scale exhibited high domain coherence. The strong convergent validity with the Qualiveen-SF (r<\/em> = 0.66) and the high Cronbach’s alpha (0.81) confirm that the established factor model functions effectively within Brazilian neurogenic cohorts<\/span>.<\/p>\n Anthoine, E., Moret, L., Regnault, A., S\u00e9bille, V., & Hardouin, J. B. (2014). Sample size used to validate a scale: A review of publications on newly-developed patient reported outcomes measures. Health and Quality of Life Outcomes<\/em>, 12, Article 176. https:\/\/doi.org\/10.1186\/s12955-014-0176-2<\/a><\/p>\n Barry, M. J., Fowler, F. J., O’Leary, M. P., Bruskewitz, R. C., Holtgrewe, H. L., Mebust, W. K., & Cockett, A. T. (1992). The American Urological Association symptom index for benign prostatic hyperplasia. The Journal of Urology<\/em>, 148(5), 1549\u20131557. https:\/\/doi.org\/10.1016\/S0022-5347(17)36966-5<\/a><\/p>\n Beaton, D. E., Bombardier, C., Guillemin, F., & Ferraz, M. B. (2000). Guidelines for the process of cross-cultural adaptation of self-report measures. Spine<\/em>, 25(24), 3186\u20133191. https:\/\/doi.org\/10.1097\/00007632-200012150-00014<\/a><\/p>\n Bellucci, C. H., Castro, F. S., Gomes, C. M., Bessa, J., Jr., Battistella, L. R., & de Fraga, R. (2015). Contemporary trends in the epidemiology of traumatic spinal cord injury: Changes in age and etiology. Neuroepidemiology<\/em>, 44(2), 85\u201390. https:\/\/doi.org\/10.1159\/000371519<\/a><\/p>\n Bonniaud, V., Bryant, D., Parratte, B., & Guyatt, G. (2006). Qualiveen: A urinary disorder-specific instrument for use in clinical trials in multiple sclerosis. Archives of Physical Medicine and Rehabilitation<\/em>, 87(12), 1661\u20131663. https:\/\/doi.org\/10.1016\/j.apmr.2006.08.345<\/a><\/p>\n Calado, A. A., Araujo, E. M., Barroso, U., Jr., Netto, J. M., Filho, M. Z., Macedo, A., Jr., Bagli, D., & Farhat, W. (2010). Cross-cultural adaptation of the Dysfunctional Voiding Symptom Score (DVSS) questionnaire for Brazilian children. International Brazilian Journal of Urology<\/em>, 36(4), 458\u2013463. https:\/\/doi.org\/10.1590\/S1677-55382010000400009<\/a><\/p>\n Cintra, L. K. L., Bessa, J., Jr., Kawahara, V. I., Ferreira, T. P. A., Srougi, M., Battistella, L. R., Souza, D. R., Bruschini, H., & Gomes, C. M. (2019). Cross-cultural adaptation and validation of the Neurogenic Bladder Symptom Score for Brazilian Portuguese. International Brazilian Journal of Urology<\/em>, 45(4), 805\u2013814. https:\/\/doi.org\/10.1590\/s1677-5538.ibju.2018.0335<\/a><\/p>\n Clark, R., Welk, B., & Baverstock, R. (2016). Patient reported outcome measures in neurogenic bladder. Translational Andrology and Urology<\/em>, 5(1), 22\u201331. https:\/\/doi.org\/10.3978\/j.issn.2223-4683.2015.12.07<\/a><\/p>\n Costa, P., Perrouin-Verbe, B., Colvez, A., Didier, J., Marquis, P., Marrel, A., Leriche, B., & Group, Q. S. (2001). Quality of life in spinal cord injury patients with urinary difficulties: Development and validation of Qualiveen. European Urology<\/em>, 39(1), 107\u2013113. https:\/\/doi.org\/10.1159\/000052421<\/a><\/p>\n D’Ancona, C. A., Tamanini, J. T., Castro, S., & Rodrigues Netto, N., Jr. (2009). Quality of life of neurogenic patients: Translation and validation of the Portuguese version of Qualiveen. International Urology and Nephrology<\/em>, 41(1), 29\u201334. https:\/\/doi.org\/10.1007\/s11255-008-9402-3<\/a><\/p>\n Danielsen, A. K., Pommergaard, H. C., Burcharth, J., Angenete, E., & Rosenberg, J. (2015). Translation of questionnaires measuring health-related quality of life is not standardized: A literature-based research study. PLOS ONE<\/em>, 10(5), Article e0127050. https:\/\/doi.org\/10.1371\/journal.pone.0127050<\/a><\/p>\n Fragal\u00e0, E., Privitera, S., Giardina, R., Di Rosa, A., Russo, G. I., Favilla, V., Castelli, T., & Cimino, S. (2015). Association between the Neurogenic Bladder Symptom Score and urodynamic examination in multiple sclerosis patients with lower urinary tract dysfunction. International Neurourology Journal<\/em>, 19(4), 272\u2013277. https:\/\/doi.org\/10.5213\/inj.2015.19.4.272<\/a><\/p>\n Guillemin, F., Bombardier, C., & Beaton, D. (1993). Cross-cultural adaptation of health-related quality of life measures: Literature review and proposed guidelines. Journal of Clinical Epidemiology<\/em>, 46(12), 1417\u20131432. https:\/\/doi.org\/10.1016\/0895-4356(93)90142-N<\/a><\/p>\n Keszei, A. P., Novak, M., & Streiner, D. L. (2010). Introduction to health measurement scales. Journal of Psychosomatic Research<\/em>, 68(4), 319\u2013323. https:\/\/doi.org\/10.1016\/j.jpsychores.2010.01.006<\/a><\/p>\n McKenna, S. P. (2011). Measuring patient-reported outcomes: Moving beyond misplaced common sense to hard science. BMC Medicine<\/em>, 9, Article 86. https:\/\/doi.org\/10.1186\/1741-7015-9-86<\/a><\/p>\n Mokkink, L. B., Terwee, C. B., Patrick, D. L., Alonso, J., Stratford, P. W., Knol, D. L., Bouter, L. M., & de Vet, H. C. (2010). The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. Journal of Clinical Epidemiology<\/em>, 63(7), 737\u2013745. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.02.006<\/a><\/p>\n Narang, G. L., & Welk, B. (2017). Patient-reported outcome measures in urology. Current Opinion in Urology<\/em>, 27(4), 366\u2013373. https:\/\/doi.org\/10.1097\/MOU.0000000000000412<\/a><\/p>\n Tamanini, J. T., D’Ancona, C. A., Botega, N. J., & Rodrigues Netto, N., Jr. (2004). Validation of the “International Consultation on Incontinence Questionnaire — Short Form” (ICIQ-SF) for Portuguese. Revista de Sa\u00fade P\u00fablica<\/em>, 38(3), 438\u2013444. https:\/\/doi.org\/10.1590\/S0034-89102004000300015<\/a><\/p>\n Terwee, C. B., Bot, S. D., de Boer, M. R., van der Windt, D. A., Knol, D. L., Dekker, J., Bouter, L. M., & de Vet, H. C. (2007). Quality criteria were proposed for measurement properties of health status questionnaires. Journal of Clinical Epidemiology<\/em>, 60(1), 34\u201342. https:\/\/doi.org\/10.1016\/j.jclinepi.2006.03.012<\/a><\/p>\n Welk, B., Morrow, S., Madill, A., & Baverstock, R. (2013). The conceptualization and development of a patient-reported neurogenic bladder symptom score. Research and Reports in Urology<\/em>, 5, 129\u2013137. https:\/\/doi.org\/10.2147\/RRU.S50560<\/a><\/p>\n Welk, B., Morrow, S., Madill, A., & Baverstock, R. (2014). The validity and reliability of the Neurogenic Bladder Symptom Score. The Journal of Urology<\/em>, 192(2), 452\u2013457. https:\/\/doi.org\/10.1016\/j.juro.2014.01.027<\/a><\/p>\n Welk, B., Lenherr, S., Elliott, S., Stoffel, J., Presson, A. P., Zhang, C., & Myers, J. (2017). A pilot study of the responsiveness of the Neurogenic Bladder Symptom Score (NBSS). Canadian Urological Association Journal<\/em>, 11(11), 376\u2013380. https:\/\/doi.org\/10.5489\/cuaj.4833<\/a><\/p>\n2. Keywords<\/h2>\n
3. Authors<\/h2>\n
\n
4. Purpose<\/h2>\n
5. Psychological Construct<\/h2>\n
Incontinence Domain<\/h3>\n
\n
Storage and Voiding Domain<\/h3>\n
\n
Consequences Domain<\/h3>\n
\n
Global Quality of Life and Bladder Management<\/h3>\n
6. Theoretical Framework<\/h2>\n
The Wilson and Cleary Model of Patient Outcomes<\/h3>\n
\n
The WHO International Classification of Functioning (ICF)<\/h3>\n
\n
7. Validity<\/h2>\n
Content Validity<\/h3>\n
Convergent Construct Validity<\/h3>\n
\n
Discriminant and Known-Groups Validity<\/h3>\n
\n
8. Reliability<\/h2>\n
Internal Consistency<\/h3>\n
\n
Test-Retest Reliability and Temporal Stability<\/h3>\n
\n
9. Factor Analysis<\/h2>\n
Original Structural Model (Welk et al.)<\/h3>\n
\n
Cross-Cultural Structural Alignment<\/h3>\n
10. Instrument \/ Measurement Tool<\/h2>\n
\n
\n
\n
11. Permissions & Fee and Test Year<\/h2>\n
\n
12. References<\/h2>\n